Public filing of Form F-4 represents important milestone in transaction towards Xanadu becoming first and only publicly traded pure-play photonic quantum computing company.The proposed transaction, which is expected to close in the first quarter of 2026, supports Xanadu’s photonic quantum computing approach, its leading PennyLane software platform, and its efforts towards building a commercially viable fault-tolerant quantum computer. TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Xanadu Quantum Technologies In ...

Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell ampl ...

Los Angeles, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Triller Group Inc (Nasdaq: ILLR; ILLRW) (“Triller” or the “Company”) announced the successful completion of its comprehensive post-merger restructuring and audit processes related to the October 2024 business combination with legacy Triller Corp., and the filing with the SEC of its outstanding periodic reports. The Company, as of January 27, 2026, is again in full compliance with its periodic reporting obligations with the SEC and with Nasdaq. The SEC’s Edgar f ...

SUZHOU, China, Jan. 28, 2026 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions, today announced that it has received a written notification (the “Deficiency Letter”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 26, 2026, indicating that for the last 30 consecutive business days, the closing bid price of the Company’s American depositary sha ...

Core Insights - Stack Capital Group Inc. has invested $5 million USD in X-energy Reactor Company, an advanced nuclear technology firm focused on developing next-generation small modular reactors and proprietary nuclear fuel solutions [1][2]. Company Overview - X-energy, founded in 2009 and based in Rockville, Maryland, specializes in safe, reliable, and carbon-free energy solutions, including the Xe-100 small modular reactor and TRISO-X particle fuel [2]. - The company has secured approximately $1.8 billion in private capital and up to $1.2 billion in funding from the U.S. Department of Energy through the Advanced Reactor Demonstration Program [2]. - X-energy is supported by major stakeholders such as Amazon, Dow Inc., and Ontario Power Generation, positioning it as a leader in advanced nuclear commercialization [2]. Industry Context - The demand for reliable, carbon-free baseload power is critical for global economic growth, especially with the rise of AI, electrification, and industrial decarbonization [4]. - Advanced nuclear energy is seen as a scalable solution to meet this demand, with X-energy recognized as a category leader due to its differentiated technology and commercial traction [4].

Core Viewpoint - Hecate Energy Group LLC and EGH Acquisition Corp. are set to host an investor webinar on February 5, 2026, to discuss Hecate's operations and strategy, including a proposed transaction for Hecate to become publicly listed on Nasdaq [1][2]. Company Overview - Hecate Energy, based in Chicago, is a prominent U.S. developer of utility-scale energy parks with a diversified portfolio that includes solar, battery storage, wind, and thermal generation [3]. - Founded in 2012, Hecate has developed projects totaling five gigawatts (GW) to construction or operations and has sold over 12 GW of power plant and storage projects [3]. - The company has established over 50 power purchase agreements (PPAs) and similar contracts exceeding 6 GW of capacity with 24 counterparties, alongside projects selling through U.S. wholesale power markets [4]. Financial Highlights - Hecate has developed over five GW of projects currently under construction or in operation, representing investments exceeding $6 billion [4]. - The company has an active development pipeline of over 47 GW of power projects [4]. Business Combination Details - EGH Acquisition Corp. aims to merge with Hecate, focusing on the power market and energy transition sectors, targeting industries that require reliable and cost-effective power solutions [5]. - EGH plans to file a registration statement with the SEC regarding the business combination, which will include a preliminary proxy statement/prospectus [6].

Core Viewpoint - Deep Sea Minerals Corp. is positioned to benefit from the NOAA's deep-sea mapping initiative, which aims to enhance understanding of deep-sea mineral systems and support future policy and resource planning [1][2][3] Industry Insights - The NOAA program will focus on high-resolution seabed mapping, geological characterization, and environmental baseline data collection in federal waters offshore American Samoa, contributing to a broader U.S. government effort to improve scientific understanding of domestic deep-sea mineral systems [2][3] - The initiative is part of the U.S. Department of Commerce's offshore critical minerals agenda, emphasizing the strategic importance of securing access to critical minerals for national defense, advanced manufacturing, energy transition, and emerging technologies [3][4] - As geopolitical competition for critical minerals intensifies, the U.S. and allied nations are increasingly focusing on domestic and allied-controlled sources, including deep seabed resources [5] Company Strategy - Deep Sea Minerals Corp. is focused on evaluating opportunities to support the future supply of critical minerals through the acquisition, exploration, and development of deep-sea mineral assets [6][7] - The company's strategy includes identifying jurisdictions and geological settings with potential exposure to polymetallic nodule systems, which contain metals relevant to defense, industrial manufacturing, clean energy infrastructure, and advanced electronics [7] - The company has begun early-stage engagement with selected governments and regulatory bodies in the Pacific Ocean region to explore potential pathways for future exploration initiatives [8]

Core Insights - The FDA has granted Breakthrough Therapy Designation to Biogen's litifilimab (BIIB059) for treating cutaneous lupus erythematosus (CLE), recognizing the urgent need for new therapies in this area [1][2][3] Company Overview - Biogen is a leading biotechnology company founded in 1978, focused on pioneering innovative science to deliver new medicines and create value for shareholders [10] - The company is advancing litifilimab as a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) for CLE, with ongoing clinical trials [3][5] Product Information - Litifilimab is a humanized IgG1 monoclonal antibody targeting BDCA2, currently under investigation for systemic lupus erythematosus (SLE) and CLE [5][6] - The drug has shown promise in reducing skin disease activity in CLE patients, as evidenced by results from the Phase 2 LILAC study [2][6] Clinical Development - The FDA's designation aims to expedite the development and review process for litifilimab, which is currently being evaluated in the AMETHYST Phase 3 study, with data readout expected in 2027 [3][6] - The current standard of care for CLE includes topical steroids, antimalarials, and immunosuppressants, but these do not alter disease progression [2][6] Industry Context - CLE is a chronic autoimmune skin disease that significantly impacts patients' quality of life, with symptoms including rash, pain, and potential irreversible skin damage [8][9] - The Lupus Research Alliance emphasizes the need for effective therapies that can alter the disease course, highlighting the importance of incorporating patient voices in drug development [4]

Core Insights - AlphaTON Capital Corp has raised a net $44 million in capital and is generating revenue through its AI infrastructure associated with Telegram's Cocoon AI [1][3] - The company is focused on establishing itself as a foundational provider of privacy-preserving artificial intelligence infrastructure [1][3] Financial and Capital Strategy - AlphaTON has executed a disciplined capital strategy to fund infrastructure expansion while maintaining financial flexibility [2] - The company closed a $15 million registered direct offering at $1.00 per share, with proceeds primarily allocated to GPU AI infrastructure scaling and working capital [4] - A $46 million investment in AI infrastructure expansion was initiated, involving the deployment of 576 NVIDIA B300 chips, projected to deliver a 27% IRR and 282% ROI [4] AI Infrastructure and Revenue Generation - AlphaTON has rapidly deployed GPU infrastructure to capitalize on the emerging opportunity in privacy-preserving AI compute [2] - The company began generating revenue from AI inference processing in December 2025 following the launch of the Cocoon AI network [4] Strategic Partnerships and Technology Integration - AlphaTON has established partnerships, including a definitive agreement with Midnight Foundation, to create additional revenue streams and vertically integrate into its Confidential Compute AI Infrastructure [2][4] - The launch of the AlphaTON Claude Connector combines Anthropic's Claude AI with TON blockchain technology, enabling users to manage digital assets through natural-language conversations [4] Management Commentary - The CEO emphasized the transformation from a passive digital asset holder to an active infrastructure operator generating recurring revenue [3] - The management team has demonstrated decisive action and efficient capital deployment, aiming to develop a vertically integrated Telegram ecosystem that combines AI and decentralized blockchain infrastructure [5]

Core Insights - Vera Therapeutics has appointed Matt Skelton as Chief Commercial Officer to lead the commercial launch of atacicept for IgA nephropathy [1][2] - Atacicept is a promising investigational treatment that targets B-cell activation and has shown significant clinical efficacy in trials [3][4][6] Company Overview - Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases [10] - The company's lead product candidate, atacicept, is designed to block B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which are involved in autoimmune diseases [10] Leadership Appointment - Matt Skelton brings extensive experience in global commercialization, having previously scaled Seagen's commercial organization from one product to four approved products [2][10] - His leadership is expected to be critical in transitioning Vera Therapeutics into a commercial-stage company [2] Atacicept Clinical Program - The ORIGIN Phase 2b clinical trial of atacicept met its primary and key secondary endpoints, showing significant reductions in proteinuria and stabilization of eGFR [4] - The ongoing ORIGIN 3 Phase 3 trial has also met its primary endpoint with a statistically significant reduction in proteinuria at week 36 [5] Regulatory Status - Atacicept has received Breakthrough Therapy Designation from the FDA for IgA nephropathy, indicating its potential to significantly improve treatment outcomes [6] - The Biologics License Application (BLA) for atacicept has received Priority Review designation, with a target action date set for July 7, 2026 [7] Future Studies - The ORIGIN Extend study allows participants to access atacicept until its commercial availability and collects long-term safety and efficacy data [8] - Atacicept is also being evaluated in other autoimmune kidney diseases, expanding its potential therapeutic applications [8][10]